BioSpace News Archive

MorphoSys AG reported preliminary Monjuvi ® U.S. net product sales and gross margin for Monjuvi U.S. net product sales for the full year of 2023 and provides its 2024 financial guidance.

Life has a challenging tempo. Sometimes, it moves faster or slower than we’d like. Nevertheless, we adapt. We pick up the rhythm of conversations.

NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted NT-I7 (efineptakin alfa) (rhIL-7-hyFc) Orphan Drug Designation (ODD) for the treatment of pancreatic cancer.

Danaher Corporation announced results for the fourth quarter and full year 2023. All results in this release reflect only continuing operations unless otherwise noted.

Kraig Biocraft Laboratories, Inc., signs key Memorandum of Understanding with the Vietnam Sericulture Association and the Lam Dong Agro-Forestry Research Experiment Center.

Today, Astellas Pharma Canada, Inc. announced that Health Canada has approved a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced publication of proteomic analyses that further demonstrate the unique role of the soluble protein CCL24 in driving pathologies associated with the rare fibrotic liver disease primary sclerosing cholangitis (PSC).

Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases.

Iterum Therapeutics today announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin® (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTIs).

Superior HealthPlan, the leading managed care organization in the state of Texas and a wholly owned subsidiary of Centene Corporation, is celebrating an important milestone – 25 years of delivering high-quality, local health care to Texans across all 254 counties throughout the state.